These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 36298791)
1. Susceptibility to Resurgent COVID-19 Outbreaks Following Vaccine Rollouts: A Modeling Study. Neofotistos G; Angeli M; Mattheakis M; Kaxiras E Viruses; 2022 Oct; 14(10):. PubMed ID: 36298791 [TBL] [Abstract][Full Text] [Related]
2. Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority. Fisman DN; Amoako A; Simmons A; Tuite AR PLoS One; 2024; 19(4):e0297093. PubMed ID: 38574059 [TBL] [Abstract][Full Text] [Related]
3. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602 [TBL] [Abstract][Full Text] [Related]
4. The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study. Zhou W; Tang B; Bai Y; Shao Y; Xiao Y; Tang S Vaccine; 2022 Nov; 40(49):7141-7150. PubMed ID: 36328883 [TBL] [Abstract][Full Text] [Related]
5. Modeling the effect of the vaccination campaign on the COVID-19 pandemic. Angeli M; Neofotistos G; Mattheakis M; Kaxiras E Chaos Solitons Fractals; 2022 Jan; 154():111621. PubMed ID: 34815624 [TBL] [Abstract][Full Text] [Related]
6. Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States. Yang F; Tran TN; Howerton E; Boni MF; Servadio JL BMC Med; 2023 Aug; 21(1):321. PubMed ID: 37620926 [TBL] [Abstract][Full Text] [Related]
7. Modelling the impact of hybrid immunity on future COVID-19 epidemic waves. Le TP; Abell I; Conway E; Campbell PT; Hogan AB; Lydeamore MJ; McVernon J; Mueller I; Walker CR; Baker CM BMC Infect Dis; 2024 Apr; 24(1):407. PubMed ID: 38627637 [TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. Swan DA; Bracis C; Janes H; Moore M; Matrajt L; Reeves DB; Burns E; Donnell D; Cohen MS; Schiffer JT; Dimitrov D Sci Rep; 2021 Jul; 11(1):15531. PubMed ID: 34330945 [TBL] [Abstract][Full Text] [Related]
10. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
11. A generalized distributed delay model of COVID-19: An endemic model with immunity waning. Iyaniwura SA; Musa R; Kong JD Math Biosci Eng; 2023 Jan; 20(3):5379-5412. PubMed ID: 36896550 [TBL] [Abstract][Full Text] [Related]
12. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607 [TBL] [Abstract][Full Text] [Related]
13. Modeling the health impact of increasing vaccine coverage and nonpharmaceutical interventions against coronavirus disease 2019 in Ghana. Ofori SK; Schwind JS; Sullivan KL; Chowell G; Cowling BJ; Fung IC Pathog Glob Health; 2024 May; 118(3):262-276. PubMed ID: 38318877 [TBL] [Abstract][Full Text] [Related]
14. Mathematical modelling of vaccination rollout and NPIs lifting on COVID-19 transmission with VOC: a case study in Toronto, Canada. Aruffo E; Yuan P; Tan Y; Gatov E; Moyles I; Bélair J; Watmough J; Collier S; Arino J; Zhu H BMC Public Health; 2022 Jul; 22(1):1349. PubMed ID: 35841012 [TBL] [Abstract][Full Text] [Related]
15. A COVID-19 vaccination model for Aotearoa New Zealand. Steyn N; Plank MJ; Binny RN; Hendy SC; Lustig A; Ridings K Sci Rep; 2022 Feb; 12(1):2720. PubMed ID: 35177804 [TBL] [Abstract][Full Text] [Related]
16. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia. McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236 [TBL] [Abstract][Full Text] [Related]
17. Serological surveillance of healthcare workers to evaluate natural infection- and vaccine-derived immunity to SARS-CoV-2 during an outbreak in Dili, Timor-Leste. Arkell P; Gusmao C; Sheridan SL; Tanesi MY; Gomes N; Oakley T; Wapling J; Alves L; Kopf S; Sarmento N; Barreto IDC; Amaral S; Draper AD; Coelho D; Guterres H; Salles A; Machado F; Fancourt NS; Yan J; Marr I; Macartney K; Francis JR Int J Infect Dis; 2022 Jun; 119():80-86. PubMed ID: 35358723 [TBL] [Abstract][Full Text] [Related]
18. Modeling waning and boosting of COVID-19 in Canada with vaccination. Childs L; Dick DW; Feng Z; Heffernan JM; Li J; Röst G Epidemics; 2022 Jun; 39():100583. PubMed ID: 35665614 [TBL] [Abstract][Full Text] [Related]
19. Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: evidence of a waning immunity. Pierobon A; Zotto AD; Antico A; De Antoni ME; Vianello L; Gennari M; Di Caprio A; Russo F; Brambilla G; Saugo M Clin Microbiol Infect; 2022 Apr; 28(4):614.e5-614.e7. PubMed ID: 34958917 [TBL] [Abstract][Full Text] [Related]
20. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]